CHF Solutions Announces Launch of Ultrafiltration Therapy Using Aquadex FlexFlow® System at Memphis Methodist Le Bonheur Healthcare System
EDEN PRAIRIE, Minn., Dec. 03, 2019 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced that Memphis, Tennessee-based health system, Methodist Le Bonheur, has initiated offering aquapheresis therapy to patients suffering from fluid overload using the company’s Aquadex FlexFlow system. The use of the therapy was featured in the Daily Memphian newspaper on November 16, 2019.
“As a company, we are dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation,” said John Erb, CEO of CHF Solutions. “We are proud and honored to be working with Methodist Healthcare system and look forward to partnering with their clinicians in the care of their fluid overloaded patients.”
“We are pleased to offer Aquadex FlexFlow therapy to our patients suffering from fluid overload,” said John Jefferies, MD, Co-Director, Methodist Cardiovascular Service Line and Jay Michael Sullivan Distinguished Chair in Cardiology at the University of Tennessee Health Science Center. “We feel this simplified form of ultrafiltration may improve the quality of life of our fluid overloaded patients and could lead to fewer rehospitalizations and reduce overall costs.”
Methodist Le Bonheur Healthcare (MLH) is an integrated, not-for- profit healthcare system based in Memphis, Tennessee, with locations and partners across the Mid-South. Throughout its history, MLH has remained affiliated with the United Methodist Church. Faith inspires the hospital to serve its patients and improve the health of its entire community.
“We continue to invest in our field therapy support organization to ensure the Aquadex FlexFlow system is providing optimal therapy to patients suffering from excess fluid,” said Nestor Jaramillo, CCO of CHF Solutions. “We are excited about this partnership with Methodist Le Bonheur and the potential to significantly improve clinical and economic outcomes with the Aquadex FlexFlow system technology.”
About CHF Solutions
CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on developing, manufacturing, and commercializing the Aquadex FlexFlow system for ultrafiltration therapy. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.
About Aquadex FlexFlow® System
The Aquadex FlexFlow system is a clinically proven therapy that provides a safe, effective, and predictable method of removing excess fluid from patients suffering from fluid overload. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and for extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. The company has submitted an application to the FDA requesting for 510(k) clearance of the Aquadex FlexFlow system to include pediatric patients who weigh 20kg or more. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding improvements to clinical and economic outcomes through use of the Aquadex FlexFlow system. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
